Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a report released on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Cellectis Price Performance

Shares of CLLS opened at $2.85 on Tuesday. Cellectis has a 52 week low of $0.96 and a 52 week high of $3.77. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.58. The firm has a market cap of $158.40 million, a price-to-earnings ratio of -1.66 and a beta of 3.08. The stock has a 50 day moving average of $2.74 and a 200-day moving average of $2.83.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, April 29th. The biotechnology company reported ($0.64) earnings per share for the quarter. The business had revenue of $1.99 million for the quarter. Cellectis had a negative net margin of 1,087.66% and a negative return on equity of 99.88%. As a group, analysts forecast that Cellectis will post -1.06 EPS for the current year.

Hedge Funds Weigh In On Cellectis

An institutional investor recently raised its position in Cellectis stock. Principal Financial Group Inc. lifted its position in shares of Cellectis S.A. (NASDAQ:CLLS) by 6.2% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 424,533 shares of the biotechnology company’s stock after acquiring an additional 24,906 shares during the period. Principal Financial Group Inc. owned 0.76% of Cellectis worth $1,125,000 as of its most recent filing with the SEC. 63.90% of the stock is owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.